Comerica Bank
CLDX icon

Comerica Bank’s Celldex Therapeutics CLDX Stock Holding History

Comerica Bank’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$830 Hold
31
– – ﹤0.01% 3597
2025
Q3 		$791 Hold
31
– – ﹤0.01% 3606
2025
Q2 		$622 Buy
31
+16
+107% +$311 ﹤0.01% 3607
2025
Q1 		$262 Buy
+15
New +$335 ﹤0.01% 3639
2013
Q4 		– Sell
-507
Closed -$270K – 2290
2013
Q3 		$270K Buy
+507
New +$174K ﹤0.01% 2286

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Comerica Bank's CLDX Position: Q4 2025 in Review

Comerica Bank held its Celldex Therapeutics (CLDX) position steady in Q4 2025 at 31 shares worth $830. The position accounts for ﹤0.01% of the portfolio, ranked #3597.

Comerica Bank first reported a position in CLDX in Q3 2013 and has held it in 5 quarters since. The position peaked at $270K in Q3 2013. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

  • Comerica Bank held 31 shares of Celldex Therapeutics worth $830 as of Q4 2025.
  • Comerica Bank left its Celldex Therapeutics share count unchanged in Q4 2025.
  • Celldex Therapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3597 holding.
  • Comerica Bank first reported a position in Celldex Therapeutics in Q3 2013 and has held it in 5 quarters since.
  • Comerica Bank's Celldex Therapeutics position peaked at $270K in Q3 2013.
  • 185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.